Vaccines Today—November 14, 2025

This week’s vaccines report covers early-phase safety/immunogenicity, durable T-cell activity, real-world effectiveness, and new oral-vaccine trials.

In Today’s Newsletter

Dive deeper

🦠 Lassa Fever Vaccine Shows Promise in Phase 1 Trial [1] [07 Nov 2025]

http://www.cidrap.umn.edu/lassa/lassa-vaccine-candidate-provides-encouraging-results-phase-1-trial
Context: The vaccine could provide an urgent solution to prevent Lassa fever, a disease endemic to parts of West Africa.
Key point: rVSVΔG-LASV-GPC, a Lassa fever vaccine, demonstrated strong immune responses and safety in a Phase 1 trial.
Implication: If successful, this vaccine could be pivotal in preventing Lassa fever outbreaks and mitigating public health threats.

🇨🇳 Akeso Advances mRNA Cancer Vaccine for Pancreatic Cancer [2] [China • 10 Nov 2025]

http://www.manilatimes.net/2025/11/10/tmt-newswire/pr-newswire/akeso-announces-first-patient-dosed-in-phase-i-trial-of-personalized-mrna-vaccine-ak154-as-monotherapy-or-in-combination-with-cadonilimab-or-ivonescimab-for-adjuvant-treatment-of-pancreatic-cancer/2219975
Context: AK154 is being tested both as a monotherapy and in combination with Akeso’s bispecific antibodies.
Key point: First patient dosed in Phase 1 trial for AK154, a personalized mRNA vaccine targeting pancreatic cancer.
Implication: This trial represents a breakthrough in targeted cancer vaccines, with potential for improving treatment outcomes for pancreatic cancer.

🧬 Evaxion Presents New Immune Data for EVX-01 in Melanoma [3] [08 Nov 2025]

http://www.manilatimes.net/2025/11/08/tmt-newswire/globenewswire/evaxion-presents-new-immune-data-from-phase-2-trial-with-ai-designed-personalized-cancer-vaccine-evx-01/2219309
Context: Data from the Phase 2 trial demonstrates a strong immune response, with durable T-cell activity in patients.
Key point: EVX-01, an AI-designed personalized vaccine, shows robust T-cell responses and lasting effects in melanoma patients.
Implication: Continued success of EVX-01 could significantly impact melanoma treatment and pave the way for broader use of personalized cancer vaccines.

💉 Anixa Biosciences Moves Breast Cancer Vaccine to Phase 2 [4] [08 Nov 2025]

http://www.ad-hoc-news.de/boerse/news/ueberblick/anixa-biosciences-advances-breast-cancer-vaccine-toward-phase-2-trial/68337416
Context: The vaccine targets the α-Lactalbumin protein, which appears in some breast cancer forms.
Key point: Anixa’s breast cancer vaccine progresses to Phase 2 after positive results in Phase 1.
Implication: If successful, this vaccine could play a role in both preventing and treating breast cancer.

🦠 RTS,S/AS01E Malaria Vaccine Effectiveness Confirmed in Real-World Study [5] [11 Nov 2025]

http://www.cidrap.umn.edu/malaria/real-world-study-malaria-vaccine-effectiveness-matches-clinical-trials
Context: This Phase 4 study further validates the vaccine’s effectiveness, reinforcing its role in malaria control strategies.
Key point: The RTS,S malaria vaccine showed significant reductions in malaria incidence and severe malaria in real-world settings.
Implication: The data will help inform ongoing malaria vaccination efforts in endemic regions and support wider vaccine deployment.

🌍 South Africa Begins Trials for Fully Manufactured Oral Cholera Vaccine [6] [South Africa • 12 Nov 2025]

http://africannewsagency.com/south-africa-begins-trials-for-first-fully-manufactured-oral-cholera-vaccine/
Context: This marks a historic milestone in vaccine production and Africa’s ability to respond to cholera outbreaks.
Key point: South Africa has launched clinical trials for an oral cholera vaccine, produced entirely in-country.
Implication: Successful trials could position South Africa as a key player in cholera vaccine production for Africa and beyond.

Why it Matters

Lassa Fever: The successful development of the Lassa vaccine would offer critical protection against a disease with significant public health impacts, especially in West Africa.
Personalized Cancer Vaccines: mRNA-based vaccines like AK154 and EVX-01 are showing promising results in early clinical trials, potentially transforming cancer treatment by targeting specific mutations.
Malaria Control: The RTS,S vaccine’s real-world effectiveness supports its ongoing use in malaria-endemic regions, contributing to global malaria control goals.
Cholera Preparedness: South Africa’s cholera vaccine trials represent a significant step toward strengthening Africa’s vaccine manufacturing capacity and readiness to address public health crises.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Vaccines archive on our research hub page

FAQ

What’s the significance of the Lassa fever vaccine trial?

The Phase 1 trial for the Lassa vaccine showed promising immune responses and safety, indicating that this vaccine could be an effective tool to prevent Lassa fever outbreaks in endemic regions.

What is Akeso’s personalized cancer vaccine AK154 targeting?

AK154 is a personalized mRNA vaccine designed to target pancreatic cancer, a particularly aggressive cancer, both as a monotherapy and in combination with Akeso’s bispecific antibodies.

What did the Phase 2 trial of EVX-01 show?

The Phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine, showed strong and durable T-cell responses in melanoma patients, indicating its potential for long-lasting therapeutic effects.

What does the RTS,S malaria vaccine study show?

The real-world study of RTS,S demonstrated significant reductions in malaria incidence and severe cases in children, validating the vaccine’s effectiveness in combating malaria.

What milestone has South Africa achieved in cholera vaccine production?

South Africa has started clinical trials for its fully locally manufactured oral cholera vaccine, marking a historic achievement in the country’s ability to produce vaccines independently.

Entities / Keywords

Lassa fever, Akeso, AK154, personalized mRNA vaccine, Evaxion, EVX-01, melanoma, Anixa Biosciences, breast cancer, RTS,S malaria vaccine, South Africa, cholera vaccine.